YM155 Reverses Cabazitaxel Resistance in Castration-resistant Prostate Cancer by Reducing Survivin Expression.
Animals
Apoptosis
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Disease Models, Animal
Drug Resistance, Neoplasm
/ drug effects
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Imidazoles
/ pharmacology
Male
Mice
Naphthoquinones
/ pharmacology
Prostatic Neoplasms, Castration-Resistant
/ genetics
RNA, Messenger
/ genetics
Survivin
/ genetics
Taxoids
/ pharmacology
Xenograft Model Antitumor Assays
Castration-resistant prostate cancer
YM155
cabazitaxel
drug therapy
inhibitor of apoptosis proteins
survivin
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
22
05
2020
revised:
23
06
2020
accepted:
24
06
2020
entrez:
4
9
2020
pubmed:
4
9
2020
medline:
20
9
2020
Statut:
ppublish
Résumé
The purpose of the present study was to clarify whether treatment with YM155, a novel small-molecule inhibitor of survivin, reversed cabazitaxel resistance in castration-resistant prostate cancer (CRPC). Cabazitaxel resistance was induced in the castration-resistant prostate cancer cell line, 22Rv1-CR. In vitro and in vivo models were used to test the efficacy of YM155 and cabazitaxel. Survivin gene expression was significantly higher in 22Rv1-CR than its parent cells (22Rv1). In 22Rv1-CR cells, YM155 significantly reduced expression of the survivin gene in a concentration-dependent manner. YM155 alone was poorly effective; however, it significantly enhanced the anticancer effects of cabazitaxel on 22Rv1-CR in vitro and in vivo. Inhibition of survivin by YM155 overcomes cabazitaxel resistance in CRPC cells.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
The purpose of the present study was to clarify whether treatment with YM155, a novel small-molecule inhibitor of survivin, reversed cabazitaxel resistance in castration-resistant prostate cancer (CRPC).
MATERIALS AND METHODS
METHODS
Cabazitaxel resistance was induced in the castration-resistant prostate cancer cell line, 22Rv1-CR. In vitro and in vivo models were used to test the efficacy of YM155 and cabazitaxel.
RESULTS
RESULTS
Survivin gene expression was significantly higher in 22Rv1-CR than its parent cells (22Rv1). In 22Rv1-CR cells, YM155 significantly reduced expression of the survivin gene in a concentration-dependent manner. YM155 alone was poorly effective; however, it significantly enhanced the anticancer effects of cabazitaxel on 22Rv1-CR in vitro and in vivo.
CONCLUSION
CONCLUSIONS
Inhibition of survivin by YM155 overcomes cabazitaxel resistance in CRPC cells.
Identifiants
pubmed: 32878797
pii: 40/9/5091
doi: 10.21873/anticanres.14512
doi:
Substances chimiques
BIRC5 protein, human
0
Imidazoles
0
Naphthoquinones
0
RNA, Messenger
0
Survivin
0
Taxoids
0
cabazitaxel
51F690397J
sepantronium
UZ77T1VFBM
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5091-5095Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.